Antihypertensive drug Micatrio combination tablets launch in Japan

18 November 2016

Antihypertensive Micatrio (telmisartan/amlodipine besylate/hydrochlorothiazide), a combination drug of Micardis and amlodipine besylate and the thiazide diuretic hydrochlorothiazide (HCTZ), has been launched in Japan by Japanese drug major Astellas Pharma (TYO: 4503) and the local subsidiary of German family-owned Boehringer Ingelheim

Hypertension is a major risk factor for cardiovascular death, yet the rate of the patient undergoing treatment and keeping their blood pressure under control remains at around 30% for men and about 40% for women. By increasing the medication adherence, the combination drug is expected to improve the rate to achieve a target blood pressure.1

The newly launched Micatrio combination tablet is the first combination drug in Japan to contain the three ingredients of a renin-angiotensin inhibitor, a CCB and small dose diuretic. Compared to ARB/CCB combination formulations and ARB/HCTZ combination formulations, it is expected to have a strong antihypertensive effect that lasts for 24 hours.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK